蛋白酶体抑制剂心 血管毒性监测和管理中国专家共识（2025版）.pdfVIP

中国肿瘤临床2025年第52卷第4期ChinJClinOncol2025.Vol.52.No.4163

·指南与共识·

蛋白酶体抑制剂心血管毒性监测和管理中国专家共识（2025版）

中国抗癌协会整合肿瘤心脏病学分会《蛋白酶体抑制剂心血管毒性监测和管理中国专家共识》专家组

摘要蛋白酶体抑制剂是多发性骨髓瘤（multiplemyeloma，MM）联合治疗的重要组成部分。硼替佐米、卡非佐米和伊沙佐米已

批准用于MM治疗，并广泛用于临床。然而蛋白酶体抑制剂（proteasomeinhibitors，PIs）治疗过程中表现出多种心血管不良反应，

如心力衰竭、高血压、心律失常、缺血性心脏病、血栓栓塞等增加了多发性骨髓瘤治疗风险，影响患者的预后。因此，识别、监测并管

理PIs相关心血管不良反应对改善MM患者生存及预后至关重要。本共识就PIs相关心血管不良反应的监测及管理提出推荐意

见，旨在规范PIs的临床应用。

关键词蛋白酶体抑制剂心血管不良反应多发性骨髓瘤

doi:10.12354/j.issn.1000-8179.2025

Chineseexpertconsensusonmonitoringandmanagementofproteasomeinhibitor-in-

ducedcardiovasculartoxicity(2025edition)

ChinaAnti-CancerAssociation,IntegratedOncocardiologyBranch,ExpertPanelonChineseexpertconsensusonmonitoringandman-

agementofproteasomeinhibitor-inducedcardiovasculartoxicity(2025edition)

Correspondenceto:TongLiu;E-mail:liutongdoc@126.com;YueLi;E-mail:ly99ly@

AbstractProteasomeinhibitors(PIs)havebecomethebackboneofcombinatorialtreatmentregimensforpatientswithmultiplemyeloma

(MM).ThePIs-bortezomib,carfifilzomib,andixazomibareallapprovedfortreatmentofMM.However,thesedrugshaveshownavariety

signsofcardiovasculartoxicity,includingheartfailure,hypertension,arrhythmias,ischaemicheartdisease,andthromboembolism,whichin-

creasepatientriskassociatedwithtreatment,andnegativelyimpactpatientoutcomes.Effectivedetection,monitoring,andmanagementof

PI-relatedcardiovasculartoxicityarethusessentialforimprovingclinicaloutcomesforpatientswithMM.Thisconsensusproposesrecom-

mendationsforthemonitoringandmanagementofcardiovasculartoxicityrelatedtoPIswiththeaimofstandardizingtheirclinicalapplica-

tion.

Keywords:

proteasomeinhibitors(PIs)